Back to search

Article

Autotaxin Inhibition Ameliorates HFpEF Phenotype By Reducing LPA-Mediated Systemic Inflammation And Cardiac Remodeling

2026-08-30

Abstract excerpt

<h4>Background: </h4> HFpEF accounts for roughly half of heart failure admissions and lacks disease-modifying therapy. Autotaxin (ENPP2) generates lysophosphatidic acid (LPA), a profibrotic and pro-inflammatory bioactive lipid. Whether circulating lysophospholipid metabolism is altered in HFpEF, and whether autotaxin inhibition modifies an established experimental HFpEF phenotype, is untested. <h4>Methods:</h4> Pl...

Identifiers and source

Literature Corpus work
011ca061-95ba-566a-b213-138b4db87ae5
DOI
10.64898/2026.08.26.747366
Open publication

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Autotaxin Inhibition Ameliorates HFpEF Phenotype By Reducing LPA-Mediated Systemic Inflammation And Cardiac RemodelingDOI 10.64898/2026.08.26.747366
Select a neighboring publication to make it the new centre.